中國化學(601117.SH):擬與控股股東的子公司等設立有限合夥企業
格隆匯 12 月 14日丨中國化學(601117.SH)公佈,公司全資子公司中國化學工程第四建設有限公司(“四化建”)、中國化學工程第七建設有限公司(“七化建”)擬與公司控股股東中國化學工程集團有限公司(“中國化學集團”)全資子公司中化學建設投資集團有限公司(“建投公司”)、中國化學工程重型機械化有限公司(“重機公司”)、三級控股子公司中化學路橋建設有限公司(“路橋公司”)以及其他社會資本方共同投資設立有限合夥企業。合夥企業總認繳出資額為人民幣10.0001億元,其中四化建和七化建各出資認繳1億元。該成立目的:對西安市等區域基礎設施等項目進行投資。
四化建、七化建參與該項目投資、建設係為了發揮聯合體各方業務資源優勢,實現優勢互補,有利於提高公司參與建設工程項目等綜合競爭實力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.